Open AccessTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Author(s) -
R.K. Murthy,
S. Loi,
A. Okines,
E. Paplomata,
E. Hamilton,
S.A. Hurvitz,
N.U. Lin,
V. Borges,
V. Abramson,
C. Anders,
P.L. Bedard,
M. Oliveira,
E. Jakobsen,
T. Bachelot,
S.S. Shachar,
V. Muller,
S. Braga,
F.P. Duhoux,
R. Greil,
D. Cameron,
L.A. Carey,
G. Curigliano,
K. Gelmon,
G. Hortobagyi,
I. Krop,
S. Loibl,
M. Pegram,
D. Slamon,
M.C. Palanca-Wessels,
L. Walker,
W. Feng,
E.P. Winer
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/exjr-aa22
Subject(s) - capecitabine , trastuzumab , metastatic breast cancer , oncology , medicine , breast cancer , cancer , colorectal cancer